1.Identification of serum protein of prostate cancer with osseous metastasis
Hongyu LIU ; Zhenguo MI ; Xuebing HAN ; Sutang GUO ; Ruihong YANG
Cancer Research and Clinic 2011;23(3):197-200
Objective To identify the biomarkers which can be used of estimating the biological behaviors of prostate cancer with osseous metastasis by SELDI-TOF-MS. Methods Screening for potential tumor biomarkers of serum samples from 19 prostate cancer patients and 35 prostate cancer patients with osseous metastasis by using the technology of SELDI-TOF-MS and CM 10 protein chips (Ciphergen Inc. USA).The PBS Ⅱ protein chip reader was used to analyze the CM10 protein chips and transform the protein information into the form of spectra. The protein contents of two groups in the same mass-to-charge ratio (M/Z value) were analyzed and preceded the analysis of variance by Biomarker Wizard software. The proteins whose contents in serum were significantly different, which was distinguished the correctly groups by Biomarker Pattern software. Results The contents of 4 proteins in the two groups were significantly different and the M/Z values of these 6 proteins were from 2000 to 20 000. The relative protein content of prostate cancer patients group was higher than that of Prostate Cancer patients with osseous metastasis group at the M/Z value of 2089,4281, 3507 and 4178 [(4.63±8.03) vs (9.88±10.77), (19.78±21.46) vs (26.73±19.41), (5.46±10.14) vs (8.10±8.74), (38.01 ±26.27) vs (45.25±20.40), (P<0.05)]. The relative protein content of prostate cancer patients group was lower than that of prostate cancer patients with osseous metastasis group at the M/Z value of 15 900 and 16 081 [(11.52±16.80) vs (4.84±5.83), (8.55±12.64) vs (3.56±3.90), (P<0.05)]. Conclusion The associated serum protein in prostate cancer with osseous metastasis can be quickly and exactly diagnosed by SELDI-TOF-MS with high sensitivity and specificity. This new method will be widely used in clinical application.
2.The several problems to be paid attention to the classification of medical devices.
Ruihong MU ; Yue WANG ; Shifu GUO ; Jingli LI
Chinese Journal of Medical Instrumentation 2013;37(6):451-453
By analysis on existing problems of the classification, the suggestions were put forward to provide a reference for improving the classification of medical devices.
Equipment and Supplies
;
classification
3.Comparison of the effect of laparoscopic and open appendectomy in the treatment of perforated appendicitis
Zhifang GUO ; Jiangping WANG ; Huaxiong GENG ; Ruihong LIU
Chinese Journal of Primary Medicine and Pharmacy 2015;(18):2727-2728,2729
Objective To compare the clinical effect of laparoscopic and open appendectomy in the treat-ment of perforated appendicitis.Methods 107 patients with perforated appendicitis were selected as the research object and were divided into two groups.The observation group(54cases)received laparoscopic appendectomy while the control group (53cases)received traditional open appendectomy.The size of incision,the amount of bleeding during operation,time of operation and hospitalization and other perioperative indexes and the incidence rate of complications were compared between the two groups.Results The operation time between the two groups had no statistical significance(t =1.286,P >0.05 ).The incision size [(2.5 ±0.3)cm],the amount of intraoperative bleeding[(10.3 ±3.4)mL]and hospitalization time[(5.4 ±0.9)d]of the observation group were better than those of (4.2 ±0.4)cm,(19.4 ±4.2)mL and (6.5 ±1.1 )d in the control group,the differences were statistically significant(t =24.901,12.329,5.666,all P <0.05).The occurrence rate of complications of the observation group was 3.4%,which was lower than 15.1% of the control group,the difference was statistically significant(χ2 =3.940, P <0.05 ).Conclusion Laparoscopic appendectomy has the advantages of less trauma,faster recovery,less complications,shorter hospitalization time,etc.And its effect is better than open appendectomy and worthy of populari-zation and application.
4.Differential expression proteins detected by mass spectrometry in patients with T cell non-Hondgkin's lymphoma and their clinical value
Zongjin LIU ; Qiaohua ZHANG ; Shuling HOU ; Sutang GUO ; Ruihong YANG
Journal of Leukemia & Lymphoma 2012;21(8):468-471
Objective To find differential expression proteins in patients with T cell non-Hodgkin’ s lymphoma (T-NHL) by using surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technique and study their related clinical application value and prospect.Methods Serum protein of 36 T-NHL patients and 30 DLBCL patients were detected by the SELD1-TOF-MS technique and weak cation exchange (wcx-2) chip.Lactate dehydrogenase (LDH) was detected by biochemistry method.Beta2-microglobulin (β2-MG) was detected by enzyme-linked immunesorbent assay (ELISA).The significant different protein spectrometry were analyzed between DLBCL patients and T-NHL patients.The correlation analysis with protein spectrometry,disease staging,LDH and β2-MG were analyzed with Spearman.Results Nine potential candidate proteins,including the peak intensity of M/Z 1142.67,1451.43,1472.49,1512.03,3194.22,3267.41,3933.86,4593.12 and 9182.24,were identified in T-NHL patients.The 9 protein markers had no contact with disease staging of T-NHL (P > 0.05).The protein markers of 4593.12 and 9182.24 were high level in T-NHL patients.LDH in these two protein markers’ positive group [(290.82±29.95) U/L,(283.94±100.94) U/L] was higher than that in negative group [(169.22±55.42) U/L,(169.50±59.25) U/L](t =-3.199,P =0.004; t =-2.378,P =0.026),and LDH was positive correlation with these two protein spectrometry (r =0.265,r =0.178,P < 0.01).There was no statistically significant difference ofβ2-MG between these two protein markers’ positive group and negative group (P > 0.05).The other 7 protein markers were low level in T-NHL patients,and there was no statistically significant difference of LDH and β2-MG in these 7 protein markers (P > 0.05).Conclusion The protein marker of 4593.12 and 9182.24 may be the specific serological markers to identify T-NHL.The combination of these two protein markers and LDH may assess the tumor load,and provide guiding value for clinical treatment.
5.Different serum proteins were found between early-stage and late-stage lung cancer patients by using proteinchip technology
Ruifen TIAN ; Sutang GUO ; Xia SONG ; Yi GUO ; Ruihong YANG ; Xia ZHANG
Cancer Research and Clinic 2009;21(8):466-468
Objective To test serum differentially expressed proteins between early-stage (stage IB-ⅢA) and late-stage (stage Ⅳ) lung cancer patients by proteinchip technology and investigate its clinical value. Methods SELDI-TOF-MS and WCX-2 protein chip were used to detect the serum protein of 30 cases of early stage lung cancer patients and 30 cases of late stage lung cancer patients. The data were analyzed by using Biomarker Wizard software. Results There are ten different proteins in the serum between the two groups of lung cancer patients. Four protein markers 7978, 8139, 15 951 and 16 133 are over expressed and seven protein markers 2867, 6885, 8701, 8840, 13 781 and 13 955 are low expressed in the late group. Conclusion SELDI-TOF-MS proteinchip technology is a convenient, sensitive and high-throughput analysis method which can screen several relatively specific protein markers for late stage lung cancer from the serum samples. This selected protein markers can predict metastasis of lung cancer patients.
6.Research on miR-497 inhibiting the expression of inflammation-related genes in colon cancer cell line HCT116 using gene expression microarray
Juanjuan WANG ; Ruihong YANG ; Fuhua WANG ; Xiangyun GUO ; Xiaoyu LI ; Shufeng LIANG ; Sutang GUO
Cancer Research and Clinic 2017;29(1):1-6
Objective To analyze the effect of miR-497 high expression on the gene expression profile of colon cancer cell line HCT116. Methods MiR-497 high expressing colon cancer cell model HCT116-497 and negative control HCT116-CON were established by lentiviral transduction. The human (V2) gene expression microarray was used to identify genes that were differentially expressed between colon cancer cells overexpressing miR-497 and the controls. The candidates were subjected to the gene ontology (GO) and KEGG pathway enrichment analysis by Molecule Annotation System 3.0 (MAS3.0). The differential expression of representative genes relative to inflammation were confirmed by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results Of all the differently expressed genes, 582 genes were down-regulated by at least 3-folds, which were enriched in inflammation-related signaling pathways in colon cancer cells overexpressing miR-497. The decrease in 15 representative genes was validated by qPCR. Compared with those in HCT116-CON cells, expressions of 10 genes in HCT116-497 cells, including CACNB1, FOS, IL-29, RPS6KA2, TNFSF15, IL-11, INHBC, CSF1R, JAK3 and IL-2Rβ, were decreased significantly, and there were statistical differences (all P< 0.05) Conclusion MiR-497 inhibits the mRNA expression of inflammation-related genes in colon cancer cell line HCT116.
7.Identification of differentially expressed proteins in different ovarian tissues by SELDI-TOF MS
Fuhua WANG ; Shuli SHAO ; Chunyan WANG ; Ruihong YANG ; Yunpeng ZHANG ; Sutang GUO
Cancer Research and Clinic 2011;23(3):168-170
Objective To search for differentially expressed proteins in normal ovaries,benign,borderline and malignant ovarian tumor protein. Methods The protein from ovarial carcinoma tissue and benign ovary was drawn, and analyzed with SELDI-TOF MS. Results There are some high expression proteins in ovarian cancer tissues: M/Z 15 112.15, 15 296.79, 7560.78, 16 049.39, 7682.06, 7932.30,15 851.32, 4619.68 and 8052.10. Borderline ovarian tumor protein peak were between benign and malignant:M/Z 15 112.15, 15 851.32, 7560.78, 7682.06 and 7932.30. Conclusion There were some differentially expressed proteins in different ovarian tissue. They might lay the molecular basis for the clinical diagnosis and therapy of ovarian cancer.
8.Application of serum surface-enhanced laser desorption/ionization proteomic patterns in esophageal carcinoma
Jing WANG ; Wenjing DU ; Ruihong YANG ; Dan GUO ; Jingyi WANG ; Jie LI
Cancer Research and Clinic 2013;(2):80-83
Objective To analyse serum proteomic patterns'differences in esophageal carcinoma patients by proteinchip technology and study its clinical value.Methods Surface-enhanced laser desorption /ionization proteomic patterns and WCX-2 protein chip were respectively used to detect the serum proteomic patterns in esophageal carcinoma patients according to before and after radiation,IMRT or 2-dimensional radiotherapy and metastasis or not.The data were analyzed by using Biomarker Wizard software.Results 8 differential protein peaks whose M/Z were 2863,3884.213,1699.600,1371.126,8454.341,1141.881,1473.377,2086.908 and 2785.016 were significant before and after radiotherapy.8 protein peaks whose M/Z were 3470.098,2011.529,3395.789,2639.055,1511.632,11488.520,9546.555 and 4783.831 were significant between IMRT and 2-dimensional radiotherapy.2 protein peaks whose M/Z were 3470.098,3395.789 were significant between metastasis and not metastasis.Conclusion Serum surface-enhanced laser desorption / ionization proteomic patterns analysis has good prospects in evaluating therapeutic effect and prognosis of esophageal carcinoma patients.
9.Preliminary study of diagnosis ofhepatocellular carcinoma by protein chip technique
Yunpeng ZHANG ; Sutang GUO ; Fuhua WANG ; Yumei WU ; Ruihong YANG ; Chunyan WANG
Cancer Research and Clinic 2011;23(10):667-670
Obiective To screen serum biomarkers in patients with hepatocellular carcinoma (HCC)by SELDI-TOF-MS technique.Methods SELDI-TOF-MS technique and CM10 Protein Chip were used to detect serum protein patterns of 46 patients with primary hepatic carcinoma and 64 healthy persons.The different proteins were obtained by the Biomarker Wizard software between the patients and healthy persons.The best biomarker of primary hepatic carcinoma was selected by evaluating the sensitivity and specificity of the protein.Results 16 protein peaks were obviously different between the patients and the healthy persons (P <0.05).The protein peaks of m/z 6845.70 had the highest diagnosis value with a sensitivity of 89.1% (41/46)and specificity of 87.5 % (56/64).This protein was likely to be a part of the immunoglobulin heavy chain variable region.Conclusion The protein of m/z 6845.70 is potential biomarkers for the diagnosis of HCC.SELDI-TOF-MS technique is a quick,simple,convenient and high through-put technology for diagnosis of hepatocellular carcinoma.
10.Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry in screening breast cancer markers
Chunyan WANG ; Ruihong YANG ; Fuhua WANG ; Yumei WU ; Xinzheng LI ; Sutang GUO
Cancer Research and Clinic 2013;25(7):433-436,444
Objective To explore the application of serum SELDI proteomic patterns to screen breast cancer biomarkers.Methods Serum protein profiles of 110 breast cancer patients and 100 healthy controls were analyzed with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOFMS).The spectra were generated on weak cation exchange (WCX2) chips and protein peaks clustering and classification analyses were made using Biomaker Wizard software.Differences in protein intensity between breast cancer cases and controls were measured with the Mann-Whitney U test and adjusted for confounding in a multivariate logistic regression model.Results Forty-nine of these proteins were found to have statistically differential expression levels between breast cancer and normal control sera (P < 0.05).Based on literatures reported,six protein biomarkers,with mass-to-charge ratio (M/Z) (4376,8126,8924,3264,3968,and 9180) were selected.Proteins with M/Z 4376,4126,and 8924 were statistically significantly decreased in breast cancer cases compared to those in healthy controls (P < 0.05).Proteins with M/Z 3264,3968,and 9180 were significantly increased in breast cancer cases compared to those in healthy controls,Protein with M/Z 9180 was associated with TNM stage and Her-2 expression in breast cancer (P < 0.05).Protein with M/Z 8926 was related with lymph node metastasis (P <0.05).Conclusion These results suggest that serum SELDI protein profiling can distinguish breast cancer patients from normal subjects with relatively high sensitivity and specificity.SELDI-TOF-MS plays a valuable role in the diagnosis of breast cancer and the discovery of new tumor-specific protein biomarkers.